Itraconazole
- Generic Name
- Itraconazole
- Brand Names
- Sporanox, Tolsura
- Drug Type
- Small Molecule
- Chemical Formula
- C35H38Cl2N8O4
- CAS Number
- 84625-61-6
- Unique Ingredient Identifier
- 304NUG5GF4
- Background
One of the triazole antifungal agents that inhibits cytochrome P-450-dependent enzymes resulting in impairment of ergosterol synthesis. It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis & aspergillosis.
- Indication
For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.
- Associated Conditions
- Aspergillosis, Blastomycosis, Chromoblastomycosis, Coccidioidal meningitis, Esophageal Candidiasis, Fungal Infections, Fungal skin infection, Histoplasmosis, Onychomycosis, Oropharyngeal Candidiasis, Paracoccidioidomycosis, Penicillium marneffei infection, Pulmonary coccidioides, Sporotrichosis, Vulvovaginal Candidiasis, Disseminated Other specified protozoal diseases
- Associated Therapies
- -
Study of BIIB091 Formulations in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Biogen
- Target Recruit Count
- 59
- Registration Number
- NCT04564612
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
Drug-drug Interaction Study With TS-142 in Healthy Adult Subjects (Concomitant Administration of Itraconazole)
- First Posted Date
- 2020-09-21
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT04557163
- Locations
- 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan
Fruquintinib CYP3A Inhibitor and Inducer Study
- Conditions
- Interventions
- First Posted Date
- 2020-09-21
- Last Posted Date
- 2021-06-18
- Lead Sponsor
- Hutchison Medipharma Limited
- Target Recruit Count
- 28
- Registration Number
- NCT04557397
- Locations
- 🇺🇸
WCCT, Cypress, California, United States
Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels
- Conditions
- Interventions
- First Posted Date
- 2020-09-03
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Epizyme, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT04537715
- Locations
- 🇪🇸
Onkologikoa, Donostia, Gipuzkoa, Spain
🇺🇸California Cancer Associates for Research and Excellence, Inc. (cCARE), Encinitas, California, United States
🇺🇸Northwestern University-Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States
CCRT With Itraconazole in Locally Advanced Squamous Esophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-07-22
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- Hangzhou Cancer Hospital
- Target Recruit Count
- 38
- Registration Number
- NCT04481100
- Locations
- 🇨🇳
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong, China
A Study to Evaluate the Effect of Fluconazole, Bupropion, or Itraconazole on the Drug Levels and Safety of BMS-986235
- Conditions
- Interventions
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2022-03-25
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT04464577
- Locations
- 🇺🇸
Local Institution, Salt Lake City, Utah, United States
A Study to Investigate the Effect of CYP3A4 Inhibition on the Single Dose Pharmacokinetics of ASTX660 and the Effect of a Single Dose of ASTX660 on the Pharmacokinetics of the CYP3A4 Substrate Midazolam
- Conditions
- Interventions
- First Posted Date
- 2020-06-01
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT04411030
- Locations
- 🇺🇸
QPS Bio-kinetic, Springfield, Missouri, United States
A Study to Assess the Effects of Itraconazole and Rifampin on Lazertinib in Healthy Adult Participants
- First Posted Date
- 2020-06-01
- Last Posted Date
- 2021-03-01
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 32
- Registration Number
- NCT04410094
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Study That Evaluates the Effect of CYP3A4 Inhibition on Lu AG06466 in Healthy Men and Women
- First Posted Date
- 2020-05-28
- Last Posted Date
- 2020-08-14
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 16
- Registration Number
- NCT04405323
- Locations
- 🇺🇸
US1517, Miami, Florida, United States
A Study to Assess the Effect of a Strong CYP3A Inhibitor, on Surufatinib in Healthy Subjects
- First Posted Date
- 2020-05-04
- Last Posted Date
- 2021-02-03
- Lead Sponsor
- Hutchison Medipharma Limited
- Target Recruit Count
- 13
- Registration Number
- NCT04372407
- Locations
- 🇺🇸
Covance Clinical Research Unit, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.